CDC and FDA Recommendations for SARS-CoV-2 Booster Shots

Author(s):

Rodney Rohde, SV, SM, MB (ASCP), FACSc,Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP

Experts in the management of SARS-CoV-2 educate on CDC and FDA recommendations for approaching administration of booster vaccines, including those for special patient populations.

EP: 1.Overview of SARS-CoV-2 Virus and Subvariants

EP: 2.Defining Variants of Interest vs Variants of Concern

EP: 3.Impact of SARS-CoV-2 Subvariants on Vaccination

EP: 4.COVID-19 Booster Vaccination Protection Rates

EP: 5.Evolution of SARS-CoV-2 Variants on Booster Shot Development and Formulations

EP: 6.Defining SARS-CoV-2 Bivalent Vaccines and Optimizing Protection Through Vaccination

Now Viewing

CDC and FDA Recommendations for SARS-CoV-2 Booster Shots

EP: 1.Overview of SARS-CoV-2 Virus and Subvariants

EP: 2.Defining Variants of Interest vs Variants of Concern

EP: 3.Impact of SARS-CoV-2 Subvariants on Vaccination

EP: 4.COVID-19 Booster Vaccination Protection Rates

EP: 5.Evolution of SARS-CoV-2 Variants on Booster Shot Development and Formulations

EP: 6.Defining SARS-CoV-2 Bivalent Vaccines and Optimizing Protection Through Vaccination

EP: 7.CDC and FDA Recommendations for SARS-CoV-2 Booster Shots

EP: 8.Influenza Vaccination With SARS-CoV-2 mRNA Booster Shots

EP: 9.Long-Term Data on SARS-CoV-2 Booster Shots

EP: 10.Initiating Patient Conversations Around SARS-CoV-2 Booster Shots

EP: 11.Safety of SARS-CoV-2 Bivalent Booster Shots

EP: 12.Impact of COVID-19 Pandemic on Antimicrobial Resistance

EP: 13.Addressing Vaccine Hesitancy and Uptake for SARS-CoV-2